glp-1 medication willowbrook il Agonists: A Comprehensive Overview Medical consultation and clinical approval are required before starting. GLP 1 Weight Loss Doctors

Disclosures: Nataliya Smith: Nothing to Disclose, Breianna Hummer: Nothing to Disclose, Vernon Chinchilli: Nothing to Disclose, Ian Schreibman: Nothing to Disclose, Rohit Loomba: Eli Lilly and Company: Consultant, Kathryn Schmitz: Nothing to Disclose, Jonathan Stine: Zydus Therapeutics: Grant/Research Support, Novo Nordisk: Consultant, Galectin: Grant/Research Support, Novo Nordisk: Grant/Research Support, Astra Zeneca: Grant/Research Support, Noom: Grant/Research Support, Zydus: Grant/Research Support, Kowa: Grant/Research Support 2584 CARBOHYDRATE RESTRICTION DELIVERED VIA REMOTE CARE IMPROVES LIVER MARKERS IN INDIVIDUALS WITH OBESITY OR OVERWEIGHT AND ABNORMAL ALANINE TRANSAMINASE Shaminie Athinarayanan 1 Caroline Roberts 1 Rebecca Adams 1 Brittanie Volk 1 , 1 Virta Health Background: The prevalence of metabolic-associated steatohepatitis liver disease (MASLD) and metabolic-associated steatohepatitis (MASH) is higher among individuals with obesity

Buyer Takeaway: U.S.-only platform

Clinical Trials and FDA Approval: Wegovy received FDA approval based on the impressive outcomes of the STEP clinical trials

RELATED: Diabetes resources How much does Trulicity cost with BCBS